Control Bionics Ltd. (CBL) AI Stock Analysis

• Market Cap: AU$14.49M
• Dividend Yield: N/A
• Average Volume (3M): 181.29K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.59
• Revenue Growth: 14.84%
• EPS Growth: 39.64%
• Country: AU
• Employees: 25
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.01
• Shares Outstanding: 353,533,330
• 10 Day Avg. Volume: 329,347
• 30 Day Avg. Volume: 181,292
• PEG Ratio: 0.00
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 47 Neutral
• Price Target: AU$0.00 ▼(-100.00% Downside)

The overall score is primarily influenced by financial performance challenges, including profitability and cash flow issues. Technical analysis provides some positive signals with the stock trading above key moving averages, but valuation concerns due to negative earnings and lack of dividends weigh heavily on the score.

Control Bionics Ltd. Business Overview & Revenue Model

Company Description

Control Bionics Ltd. (CBL) is a healthcare technology company specializing in assistive communication devices for individuals with speech and movement disabilities. Operating within the medical and assistive technology sectors, CBL develops and markets innovative products that enable users to communicate through brain-computer interface technology and electromyography, providing enhanced quality of life for those with conditions such as ALS, spinal cord injuries, and cerebral palsy.

How the Company Makes Money

Control Bionics Ltd. makes money primarily through the sale of its assistive communication devices and related accessories. The company generates revenue by marketing its products directly to consumers, healthcare institutions, and through distribution partnerships. Key revenue streams include the NeuroNode technology, which combines brain-computer interface and electromyography to allow users to control devices with minimal muscle movement. The company may also engage in partnerships with healthcare providers and institutions for product trials and adoption, further contributing to its earnings.

Control Bionics Ltd. Financial Statement Overview

Summary

Control Bionics Ltd. demonstrates revenue growth but struggles with profitability and cash flow. The balance sheet is stable with low leverage, but negative return on equity and cash flow issues indicate a need for strategic improvements.

Income Statement

Control Bionics Ltd. has shown a positive revenue growth rate of 16.32% in the latest year, indicating a strong top-line performance. However, the company is struggling with profitability, as evidenced by negative net profit margins and EBIT margins. The gross profit margin remains healthy, but the consistent net losses highlight ongoing challenges in managing operational costs.

Balance Sheet

The balance sheet reflects a moderate level of financial stability with a low debt-to-equity ratio, indicating conservative leverage. However, the return on equity is negative, suggesting that the company is not generating sufficient returns on shareholder investments. The equity ratio is relatively strong, showing that a significant portion of assets is financed by equity.

Cash Flow

Cash flow analysis reveals a decline in free cash flow growth, with negative operating cash flow indicating potential liquidity issues. The free cash flow to net income ratio suggests that the company is not effectively converting its earnings into cash. This raises concerns about the company's ability to sustain operations without external financing.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	6.14M	6.14M	5.35M	5.64M	4.50M	4.09M
Gross Profit	4.11M	4.11M	3.90M	3.71M	-2.91M	2.50M
EBITDA	-5.14M	-5.14M	-5.01M	-5.14M	-5.92M	-3.40M
Net Income	-6.11M	-6.11M	-5.91M	-5.63M	-6.11M	-3.55M
Balance Sheet
Total Assets	8.23M	8.23M	9.03M	8.70M	13.44M	18.35M
Cash, Cash Equivalents and Short-Term Investments	672.66K	672.66K	980.76K	935.50K	5.21M	12.33M
Total Debt	435.40K	435.40K	961.74K	128.50K	284.82K	14.87K
Total Liabilities	2.72M	2.72M	2.76M	1.58M	1.51M	1.19M
Stockholders Equity	5.51M	5.51M	6.27M	7.15M	11.92M	17.16M
Cash Flow
Free Cash Flow	-4.57M	-4.57M	-5.38M	-4.98M	-5.75M	-4.04M
Operating Cash Flow	-4.27M	-4.27M	-4.91M	-4.53M	-5.60M	-3.99M
Investing Cash Flow	-744.78K	-744.78K	-473.09K	-457.54K	-147.74K	-53.40K
Financing Cash Flow	4.63M	4.63M	5.43M	706.43K	-87.33K	14.92M

Control Bionics Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.04
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CBL, the sentiment is Positive. The current price of 0.04 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.04, and above the 200-day MA of 0.04, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 64.94 is Neutral, neither overbought nor oversold. The STOCH value of 44.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:CBL.

Control Bionics Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AT1	50 Neutral	AU$22.68M	―	-58.27%	―	-7.20%	28.70%
CBL	47 Neutral	AU$14.49M	―	-103.74%	―	14.84%	39.64%
ADR	47 Neutral	AU$8.38M	―	-1476.79%	―	-2.82%	32.47%
UCM	46 Neutral	AU$3.12M	―	-218.52%	―	-30.80%	-38.95%
HMD	45 Neutral	€36.44M	―	-513.22%	―	-34.06%	75.47%
IRX	38 Underperform	AU$7.04M	―	-191.40%	―	―	-55.00%

Control Bionics Ltd. Corporate Events

Control Bionics Achieves Record Year with Strategic Market Expansion

Control Bionics Limited reported a record year with a 15% increase in sales revenue, driven by strong growth in the US due to the adoption of the HCPCS code and successful distribution strategies. The company is advancing its NeuroNode and NeuroStrip technologies across multiple markets, with significant interest from distributors in the US and Europe. The Australian market also showed a 20% revenue increase, and strategic partnerships are being pursued to enhance distribution. The company’s focus on innovation and strategic market expansion is positioning it for continued growth.

Control Bionics to Host Investor Webinar on Quarterly Results

Control Bionics Limited announced an upcoming investor webinar to discuss its quarterly results, with CEO Jeremy Steele presenting and answering questions. This event highlights the company’s ongoing efforts to engage stakeholders and provide transparency about its financial performance and strategic direction.

Control Bionics Limited Announces Cessation of Securities

Control Bionics Limited announced the cessation of 967,720 securities due to the expiry of options or other convertible securities without exercise or conversion as of February 28, 2025. This announcement may impact the company’s capital structure and could influence investor perceptions regarding the company’s financial strategies and market positioning.